INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,350 | $567.61 | 579,816 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,700 | $566.66 | 581,166 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,000 | $565.89 | 582,866 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,000 | $564.57 | 583,866 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 530 | $563.76 | 584,866 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $562.36 | 585,396 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,200 | $561.75 | 585,496 |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 3,806 | $559.08 | 679,012 |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 92,316 | $559.08 | 586,696 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,900 | $555.26 | 500,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.